The patient present in this article is a 9-yearold boy who had acute lymphoblastic leukemia and Down syndrome, who was diagnosed with hepatitis C infection and was successfully treated with a combination of DAA glecaprevir (250 mg/day) and pibrentasvir (100 mg/day) over 8 weeks.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Millions of people worldwide suffer from hepatitis C, which can lead to hepatitis, cirrhosis, and hepatocellular carcinoma.
📊
Key Findings & Data:The risk of hepatitis C virus (HCV) infection is increased in patients with leukemia due to the frequent need for blood transfusion.
💡
Conclusion & Impact:The patient present in this article is a 9-yearold boy who had acute lymphoblastic leukemia and Down syndrome, who was diagnosed with hepatitis C infection and was successfully treated with a combination of DAA glecaprevir (250 mg/day) and pibrentasvir (100 mg/day) over 8 weeks.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Millions of people worldwide suffer from hepatitis C, which can lead to hepatitis, cirrhosis, and hepatocellular carcinoma. The risk of hepatitis C virus (HCV) infection is increased in patients with leukemia due to the frequent need for blood transfusion. Owing to their proven effectiveness in treating HCV infection, direct-acting antivirals (DAAs) have become a new treatment approach in children older than 12 years. The patient present in this article is a 9-yearold boy who had acute lymphoblastic leukemia and Down syndrome, who was diagnosed with hepatitis C infection and was successfully treated with a combination of DAA glecaprevir (250 mg/day) and pibrentasvir (100 mg/day) over 8 weeks.
🔖
Cite This Article
BALAMTEKİN, N., GÜRSEL, O., ARSLAN, M., SELEK, A. (2022). Treatment of pediatric patients with Down syndrome, acute lymphoblastic leukemia, and hepatitis C infection by directacting antivirals. Gülhane Tıp Dergisi, Cilt: 64 - Sayı: 2, 201–203. https://ajindex.com/articles/526763
Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: The viruses and their replication. In Fields Virology. 5th ed. Philadelphia, Lippincott-Raven; 2007
Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12(Suppl 2):S2
Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606-4613
Wang X, Gao F, Yuan G, et al. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. J Viral Hepat. 2016;23:971-976
Deming P. Viral hepatitis. In: Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, NY; 2019
Indolfi G, Hierro L, Dezsofi A, et al. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:505-515
Schwarz KB, Molleston JP, Jonas MM, et al. Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C. J Pediatr Gastroenterol Nutr. 2016;62:93-96
Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;9:CD012143
Tsunoda T, Inui A, Kawamoto M, Sogo T, Komatsu H, Fujisawa T. Effects of pegylated interferon-α-2a monoterapy on growth in Japanese children with chronic hepatitis C. Hepatol Res. 2014;44:251-258.